Company: SINT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010496
Chunk: 35

Company: Sintx Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 35
---
 the Exchange Act, is recorded, processed,
summarized, and reported within the time periods specified by the Commission’s rules and forms. Disclosure controls and procedures
include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the
Exchange Act are properly recorded, processed, summarized and reported within the time periods required by the Commission’s rules
and forms.

We carried out an evaluation, under the supervision
and with the participation of our management, including our Chief Executive Officer (principal executive officer and principal financial
officer), of the effectiveness of the design and operation of these disclosure controls and procedures, as such term is defined in Exchange
Act Rule 13a-15(e), as of March 31, 2025. Based on this evaluation, the Chief Executive Officer concluded that our disclosure controls
and procedures were effective as of March 31, 2025, the end of the period covered by this Quarterly Report on Form 10-Q.

There were no changes in our internal
control over financial reporting that occurred during the first quarter of 2025 that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

We are not aware of any pending or threatened legal
proceeding against us that could have a material adverse effect on our business, operating results or financial condition. The medical
device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property
rights as well as improper hiring practices. As a result, we may be involved in various legal proceedings from time to time.

Item 1A.
Risk Factors

Information regarding risk factors appears in Item
1A of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 19, 2025. There have
been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS

On February 20, 2025, the Company entered into a private placement transaction
pursuant to a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors
for aggregate gross proceeds of $5.0 million, before deducting fees to the placement agent and other expenses payable by the Company in
connection with the Private Placement. For